Diagnostic Study for Differentiating Functional From Organic Diseases in Patients With Lower GIT Symptoms

ConditionsIrritable Bowel Syndrome (IBS)Inflammatory Bowel Disease (IBD)

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorSohag University

About this trial

The study is intended to find a new trusted, cost-effective biomarker for differentiating irritable bowel syndrome from inflammatory bowel disease to decrease the use of unnecessary invasive methods in patients with irritable bowel syndrome

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adults (≥18 years) presenting with chronic lower gastrointestinal symptoms, such as diarrhea, abdominal pain, or altered bowel habits, for a duration exceeding 6 weeks.

Patients with no prior diagnosis of IBD or IBS.

Patients willing to provide informed consent and comply with study requirements.

Those without recent use of immunosuppressants or anti-inflammatory medications that could affect biomarker levels

Disqualifiers

Patients with a confirmed diagnosis of IBD and currently on treatment.

Those with acute gastroenteritis, infectious colitis, or positive stool cultures for pathogens.

Patients diagnosed with colorectal cancer, celiac disease, or other known organic GI disorders.

Recent antibiotic, NSAID, or corticosteroid use within the past 4 weeks.

Trial population

patients with lower GIT symptoms seeking medical advice at Department of Internal Medicine, Gastroenterology Outpatient Clinic, Sohag University Hospital

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

100 Participants

are grouped into 3 trial groups

Group A: control group "normal"

Group B: case group 1 "patients with lower GIT symptoms suggestive of irritable bowel syndrome"

Group C: case group 2 "patients with lower GIT symptoms suggestive of inflammatory bowel disease"

Trial outcomes

Primary outcomes

efficacy of myeloperoxidase for differentiating irritable bowel syndrome from inflammatory bowel disease.

Number of patients with elevated myeloperoxidase in irritable bowel syndrome and those with inflammatory bowel disease.

Time frame

baseline

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sohag University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: